Is GSK plc (GSK) a Buy, Sell, or Hold?
GSK plc
NYSE:GSK
$51.63 USD
$0.38 (0.74%)
- Volume
- 1.02M
- Average Volume
- 3.83M
- Market Capitalization
- $103.4B
- P/E Ratio
- 13.22
- Dividend Yield
- 3.50%
- Price Target
- $53.00
- Year High
- $61.70
- Year Low
- $35.45
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.45
- Current Ratio
- $0.79
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Luke Victor Miels |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Current Symbol | GSK |
| CUSIP | 37733W204 |
| CIK | 0001131399 |
| Web | https://www.gsk.com |
| Phone | 44 20 8047 5000 |
| Currency | USD |
| Employees | 66841 |
| Country | GB |
Liquidity
| Debt-to-Equity Ratio | 1.07 |
| Payout Ratio | 0.45 |
| Current Ratio | 0.79 |
| Quick Ratio | 0.52 |
| Cash Ratio | 0.15 |
Sales & Book Value
| Annual Sales | $32.67B |
| Price / Sales | 2.34 |
| Cash Flow | 1.25 |
| Price / Cash Flow | 15.29 |
| Price / Book | 4.32 |
Price Target and Rating
| Average Stock Price Forecast | $53.00 |
| High Stock Price Forecast | $85.00 |
| Low Stock Price Forecast | $35.25 |
| Forecast Upside/Downside | -2.58% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 29 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $5.56 |
| Trailing P/E Ratio | 13.22 |
| PEG Ratio | 0.15 |
| P/E Growth | 0.15 |
| Net Income | $5.72B |
| Net Margin | 17.78% |
| Pretax Margin | 22.69% |
| Return on Equity | 35.78% |
| Return on Assets | 9.27% |
Financials Score
| AltmanZ Score | 1.66 |
| Piotroski Score | 7.00 |
| Working Capital | -6.16B |
| Total Assets | 82.91B |
| Ebit | 8.13B |
| Market Cap | 77.02B |
| Total Liabilities | 59.93B |
Poll Results
About GSK plc (NYSE:GSK) Stock
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides ... diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer
2026-07-14 09:31:09
GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.
2026-07-13 14:00:00
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propo
2026-07-13 13:29:00
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nuvalent, Inc. (NasdaqGS: NUVL) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Nuvalent will receive $124.00 in cash for each share of Nuvalent that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate.
UBS keeps GSK at 'neutral' with focus on chief executive's strategy update
2026-07-13 10:25:00
UBS expects investors to pay little attention to GSK PLC's (LSE:GSK, NYSE:GSK) second-quarter results, with focus shifting instead to a strategy update from...
UBS keeps GSK at 'neutral' with focus on chief executive's strategy update
2026-07-13 09:30:06
UBS expects investors to pay little attention to GSK PLC's (LSE:GSK, NYSE:GSK) second-quarter results, with focus shifting instead to a strategy update from new chief executive Luke Miels. The bank reiterated its 'neutra'l rating on GSK ahead of results and a capital markets day due on 28 July.
GSK's Jemperli meets main goal in mid-stage rectal cancer trial
2026-07-13 03:15:11
GSK said on Monday its cancer drug Jemperli met the primary goal of a mid-stage trial, with a clinically significant rate of patients showing no detectable signs of cancer for one year or more after treatment for a specific type of locally advanced rectal cancer.
GSK's targeted cancer therapy shows positive results in late-stage study
2026-07-10 07:38:49
British drugmaker GSK's experimental drug for treating patients with advanced or relapsed small-cell lung cancer showed positive results in a late-stage trial on Friday.
Alector and GSK partnership to end after dementia, Alzheimer's drug failures
2026-07-08 17:20:31
Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement covering two experimental antibody drugs after both the drug candidates suffered clinical setbacks.
Frequently Asked Questions
-
What is the current GSK plc (GSK) stock price?
-
GSK plc(NYSE:GSK) stock price is $51.63 in the last trading session. During the trading session, GSK stock reached the peak price of $61.7 while $35.45 was the lowest point it dropped to. The percentage change in GSK stock occurred in the recent session was 0.74% while the dollar amount for the price change in GSK stock was $0.38.
-
GSK's industry and sector of operation?
-
The NYSE listed GSK is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
-
Who are the executives of GSK?
-
Constantin Fest | Senior Vice President & Head of Investor Relations
Shobie Ramakrishnan | Chief Digital & Technology Officer
Luke V. Miels | Chief Executive Officer & Director
David Simon Redfern | President of Corporate Development
James Ford | Senior Vice President & Group General Counsel of Legal & Compliance -
How many employees does GSK have?
-
Number of GSK employees currently stands at 66841. GSK operates from 980 Great West Road, Brentford, None TW8 9GS, GB.
-
Link for GSK official website?
-
Official Website of GSK is: https://www.gsk.com
-
How do I contact GSK?
-
GSK could be contacted at phone #44 20 8047 5000 and can also be accessed through its website. GSK operates from 980 Great West Road, Brentford, None TW8 9GS, GB.
-
How many shares of GSK are traded daily?
-
The average number of GSK shares traded daily for last 3 months was 3.83M.
-
What is the market cap of GSK currently?
-
The market value of GSK currently stands at $103.4B with its latest stock price at $51.63